DiogenX
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $27.5M
Overview
Developing a regenerative cell therapy to restore insulin production for a functional cure for diabetes.
MetabolicRegenerative Medicine
Technology Platform
A stem cell differentiation platform engineered to generate functional, glucose-responsive pancreatic islet cells for allogeneic transplantation.
Funding History
1Total raised:$27.5M
Venture$27.5M
Opportunities
The massive global diabetes market creates a multi-billion dollar opportunity for a safe and effective curative therapy.
Risk Factors
High technical risk in achieving durable engraftment and function of transplanted cells without dangerous immune rejection.
Competitive Landscape
Faces competition from Vertex Pharmaceuticals' clinical-stage cell therapies and other biotechs in the diabetes cell therapy space, all racing to achieve a functional cure.